|Acura Pharmaceuticals, Inc.|
616 N. North Court
United States - Map
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, researches, develops, and commercializes products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets for the use as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, hydromorphone HCl, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has collaboration and license agreements with Egalet US, Inc.; Egalet Ltd.; and Egalet Corporation to manufacture and commercialize Oxaydo products worldwide. Acura Pharmaceuticals, Inc. was founded in 1935 and is based in Palatine, Illinois.
|Acura Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 1; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Robert B. Jones ,
Chief Exec. Officer, Pres and Director
|Mr. Peter A. Clemens ,
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.
|Dr. Albert W. Brzeczko Ph.D.,
VP of Technical Affairs
|Mr. James F. Emigh R.PH.,
VP of Corp. Devel.
|Mr. J. Bradley Rivet ,
VP of Marketing
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|